Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
139 hedge funds and large institutions have $305M invested in Lumos Pharma, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 53 increasing their positions, 43 reducing their positions, and 28 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 43
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 152 → 139 (-13)
25% less call options, than puts
Call options by funds: $15.1M | Put options by funds: $20.1M
43% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 28
48% less capital invested
Capital invested by funds: $588M → $305M (-$283M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$15.1M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$8.81M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.77M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.84M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.9M |
| 2 |
HA
Hays Advisory
Franklin,
Tennessee
|
-$3.78M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.54M |
| 4 |
O
OrbiMed
New York
|
-$3.11M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.05M |
LUMO Hedge Fund Activity: Q1 2016 in Review
139 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q1 2016, worth a combined $305M — down 48% from $588M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of LUMO and 16 opened new positions — a net loss of 12 holders — while 43 trimmed existing stakes and 53 added.
The largest buyer was Renaissance Technologies, adding an estimated $15.1M. The largest seller was Fidelity Investments, cutting an estimated $16.9M.
- 139 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q1 2016, down from 152 in Q4 2015.
- Funds reported $305M of Lumos Pharma, Inc. Common Stock stock for Q1 2016, down 48% quarter-over-quarter.
- 16 funds opened new Lumos Pharma, Inc. Common Stock positions in Q1 2016 and 28 closed out, a net change of -12 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q1 2016 was Renaissance Technologies, an estimated $15.1M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q1 2016 was Fidelity Investments, an estimated $16.9M sold.
Based on aggregated 13F filings for Q1 2016.